Drug treatment of true gynecomastia in overweight adult men

BACKGROUND: True gynecomastia is associated with excess body mass, which is caused by an imbalance of androgens/estrogens. Therefore, there is an interest in evaluating the possibility of drug therapy for this condition through the use of antiestrogens or aromatase inhibitors.

AIM: To evaluate the possibility of drug therapy for true gynecomastia in adult men with excess body mass through the use of clomiphene or letrozole.

MATERIALS AND METHODS: A retrospective study included men with newly developed gynecomastia and excess body mass who sought medical help at the Endocrinology Research Center from January 2020 to May 2024, and received either clomiphene therapy or letrozole for a period of 4 weeks. All patients were evaluated for the condition of their breast glands, total bilirubin, liver transaminases, creatinine, urea, luteinizing hormone, prolactin, sex hormone-binding globulin, estradiol, total testosterone, alpha-fetoprotein, and chorionic gonadotropin. The baseline level of statistical significance was set at p<0.05.

RESULTS: With clomiphene treatment, no statistically significant differences were found in the evaluated parameters, except for estradiol and testosterone levels, which increased. Clomiphene therapy worsened the condition of three patients (13% (95% CI 2,8;33,6)) - they experienced breast pain that was not present at the time of prescription. With letrozole treatment, there was a positive trend - all evaluated parameters significantly improved. Comparing the changes in the studied parameters, it was found that letrozole treatment had a better effect in terms of the severity of gynecomastia (-1[0;-1] degree), reduction in estradiol levels (-31,7[-8,8;-90,8] pmol/l), and also reduced the number of patients willing to undergo surgical removal of gynecomastia (-63,4% (95% CI -46,9;-77,9)).

CONCLUSION: The use of an aromatase inhibitor reduces the severity of gynecomastia and decreases the number of patients willing to undergo surgical removal.

1. Yashina YuN, Rozhivanov RV, Kurbatov DG. Sovremennye predstavleniya ob epidemiologii, etiologii i patogeneze ginekomastii. Andrologiya i genital’naya hirurgiya. 2014;3:8-15 (In Russ.).

2. Basaria S, Dobs AS. Endocrine causes of gynecomastia in men. UpToDate, 2023

3. Bel’cevich DG, Vanushko VE, Kuznecov NS, i dr. Ginekomastiya. Endokrinnaya hirurgiya, 2012. s. 18-23 (In Russ.).

4. Sethi MK, Singhal P, Gupta NP. Gynecomastia: An overview of the etiology, diagnosis, and treatment. Indian Journal of Endocrinology and Metabolism. 2016;20(2):171–177

5. Valeeva FV, Sharipova YuU, Gazizova GR, i dr. Ginekomastiya u muzhchin: prichiny, diagnostika, lechenie. Effektivnaya farmakoterapiya. 2023;19(52):30-39 (In Russ.). doi: https://doi.org/10.33978/2307-3586-2023-19-52-30-39

6. Baumann K. Gynecomastia-Conservative and Surgical Management. Breast Care. 2018. doi: https://doi.org/10.1159/000494276

7. Berger O, Landau Z, Talisman R. Gynecomastia: A systematic review of pharmacological treatments. Front Pediatr. 2022;10. doi: https://doi.org/10.3389/fped.2022.978311

8. Barutca S, Kutlu N, et al. Gynecomastia treatment principles: evaluation of our results. Med J Okmeydani Train Res Hospital. 2011;27:36-43

9. Swerdloff RS, Ng JCM. Gynecomastia: Etiology, Diagnosis, and Treatment. [Updated 2023 Jan 6]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA)

10. Kanakis GA, Nordkap L, Bang AK, et al. EAA clinical practice guidelines-gynecomastia evaluation and management. Andrology. 2019;7(6):778-793. doi: https://doi.org/10.1111/andr.12636

11. Stárka L, Hill M, Pospíšilová H, et al. Estradiol, obesity and hypogonadism. Physiol Res. 2020;69(Suppl 2):S273-S278. doi: https://doi.org/10.33549/physiolres.934510

12. Rodriguez KM, Pastuszak AW, Lipshultz LI. Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opin Pharmacother. 2016;17(11):1561-1567

13. Chehab M, Madala A, Trussell JC. On-label and off-label drugs used in the treatment of male infertility. Fertil Steril. 2015;103:595–604

14. Stephens S, Polotsky A. Big Enough for an Aromatase Inhibitor? How Adiposity Affects Male Fertility. Semin Reprod Med. 2013;31(04):251-257. doi: https://doi.org/10.1055/s-0033-1345272

15. Braunstein GD. Aromatase and gynecomastia. Endocr Relat Cancer. 1999;6(2):315-24. doi: https://doi.org/10.1677/erc.0.0060315

16. Zervoudis S, Iatrakis G, et al. Gynecomastia treatment with tamoxifen or tamoxifen followed by letrozole: prototype clinical study. Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 2024;38(2):99-106. doi: https://doi.org/10.61873/XVQY6568

17. Khan HN, Rampaul R, Blamey RW. Management of physiological gynaecomastia with tamoxifen. Breast. 2004;13:61–65

18. James R, Ahmed F, Cunnick G. () The efficacy of tamoxifen in the treatment of primary gynecomastia: an observational study of tamoxifen versus observation alone. Breast J. 2012;18:620–621

19. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol. 2005;23:808–815

20. Plourde PV, Reiter EO, Jou HC, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:4428–4433

21. Mauras N, Bishop K, Merinbaum D, et al. Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. J Clin Endocrinol Metab. 2009;94:2975–2978